In a recent interview with ILCN, the US FDA’s Dr. Harpreet Singh discusses the confirmatory Pragmatica-Lung trial and how the agency’s new pragmatic approach to trial design can streamline research and ultimately benefit patients. Read more
In a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint. Read more
In a Q&A with ILCN, Dr. Melissa Johnson recaps the trial’s positive results—and surprises—and discusses the potential roles sotorasib and other drugs in its class may play in treating KRAS G12C+ NSCLC. Read more
Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?
+more
Study highlights limitations of relying solely on clinical smoking history, and findings suggest tobacco smoking-related mutational signatures could potentially guide molecular testing and optimize patient stratification in clinical trials. Read more
LALCA participants recap how the field of liquid biopsy continues to grow—from new biomarkers to new frontiers in early cancer detection. Read more
ILCN Editor Dr. Corey J. Langer reflects on highlights from the past year and looks at the year to come. Read more
In a “tale of two trials,” Drs. Ogbeide and Osarogiagbon use insights from the ALCHEMIST trial population to try to understand outcomes disparities between North America and Japan. Read more
During ACLC 2022, Dr. Noemi Reguart reviewed the data for MET-targeting TKIs and monoclonal antibodies for patients with METex14 skipping mutations, MET amplification, and MET overexpression. Read more
Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration
+more
Beyond sotorasib, dozens of small molecule inhibitors are being explored to target this oncogenic driver. Get up to date as researchers from Roswell Park Comprehensive Cancer Center summarize the KRAS trial landscape. Read more
Drs. Stephanie Saw and Daniel Tan stress the importance of understanding the intricacies of HER2 testing in non-small cell lung cancer to optimize patient selection. Read more